Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 1, 2009, Pages 209-220

  Yong, Tao Li ^a,b   Young, Min Kwon ^b   Spangrude, Gerald J ^c   Liang, Jun F ^d   Hee, Sun Chung ^b   Yoon, Jeong Park ^e   Yang, Victor C ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Stevens Institute of Technology   (United States)

^e Seoul National University   (South Korea)

Author keywords

Asparaginase therapy; ATTEMPTS approach; Peptide; Prodrug; Protein transduction domain (PTD); Targeting

Indexed keywords

ASPARAGINASE THERAPY; ATTEMPTS APPROACH; PRODRUG; PROTEIN TRANSDUCTION DOMAIN (PTD); TARGETING;

AMINES; AMINO ACIDS; ANIMALS; BACTERIOPHAGES; ENZYME ACTIVITY; LIVER; ORGANIC ACIDS; PEPTIDES;

CELL MEMBRANES;

ASPARAGINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTEMPTS SYSTEM; CANCER SURVIVAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENZYME THERAPY; FEMALE; HUMAN; IN VIVO STUDY; LEUKEMIA L 5178 Y; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; SURVIVAL RATE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; GENE PRODUCTS, TAT; HEMATOLOGIC TESTS; HUMANS; LYMPH NODES; MICE; MICE, INBRED DBA; MOLECULAR SEQUENCE DATA; PEPTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 70349098869     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32204     Document Type: Article

References (20)

1. American Hospital Formulary Service (AHFS) Drugs. Asparaginase. Bethesda, MD: Hamilton Press; 2001. p 872-875.
2. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
3. Horowitz B, Madras BK, Meister A, Old LJ, Boyes EA, Stockert E. Asparagine synthetase activity of mouse leukemias. Science 1968;160:533-535.
4. Kodera Y, Sekine T, Yasukohchi T, Kiriu Y, Hiroto M, Matsushima A, Inada Y. Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in vivo and in vitro. Bioconjug Chem 1994;5:283-286.
5. Ortega JA, Nesbit ME, Donaldson MH, Hittle RE, Weiner J, Karon M, Hammond D. L-Asparaginase, vincritine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977;37:535-540. (Pubitemid 8030402)
6. Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: A report from Children's Cancer Study Group. Cancer Res 1979;39:3893-3896. (Pubitemid 10242204)
7. Jones B, Holland JF, Glidewell O, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Maurer HM, Koch K, Falkson G, Patterson R, Seligman B, Sartorius J, Kung F, Haurani F, Stuart M, Burgert EO, Ruymann F, Sawitsky A, Forman E, Pluess H, Truman J, Hakami N. Optimal use of L-asparaginase (NSC-109299) in acute lymphocytic leukemia. Med Pediatr Oncol 1977;3:387-400. (Pubitemid 8235411)
8. Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukemia receiving L-asparaginase during induction therapy: A retrospective study. The GIMEMA Group. Eur J Haematol 1992;49:63-66.
9. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 1976;38:1843-1846.
10. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 1982;100:990-995.
11. Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof of concept evaluation. J Control Release. In press.
12. Park YJ, Liang JF, Song H, Li YT, Naik SS, Yang VC. ATTEMPTS: A heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv Drug Deliv Rev 2003;55:251-265. (Pubitemid 36138815)
13. Liang JF, Li YT, Connell M, Yang VC. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system. AAPS PharmSci 2000;2: article 7.
14. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833. (Pubitemid 18224442)
15. Liu CM, Suzuki Y, Chen LP, Okayasu T, Calkins CE, Wheelock EF. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: In vivo and in vitro effects. Cancer Res 1990;50:1361-1367.
16. Zhang ZY, Chow DA. Differential CD45 isoform expression accompanies reduced natural antibody binding in L5178Y-F9 tumor progression. J Immunol 1997;159:344-350.
17. Saito T, Ueno T, Sekine T, Kodera Y, Hiroto M, Matsushima A, Nishimura H, Inada Y. Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride. Leukemia 1997;11(Suppl 3):408-409. (Pubitemid 27313551)
18. Trainer DL, Wheelock EF. Phenotype shifts in the L5178Y lymphoma population during progression of the tumor-dormant state in DBA/2 mice. Cancer Res 1984;44:1063-1071. (Pubitemid 14152794)
19. Borella L, Hamlin NM, Hiramoto R. Hematological changes in tumor-bearing mice treated with L-asparaginase active guinea pig serum. Proc Soc Exp Biol Med 1969;132:1186-1190.
20. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo transduction: Delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572.